Engineered lipase variants

Inventors: Chinping Chng (Menlo Park, CA); William Casey Hallows (San Francisco, CA); Judy Victoria Antonio Viduya (South San Francisco, CA); Nikki Dellas (San Carlos, CA); Stephanie Sue Galanie (Knoxville, TN); Kristen Jean Vallieu (Union City, CA)

Assignee: Societe des Produits Nestle S.A.

C12N9/20 A61K9/4883 A61K38/465 A61P5/48

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12680091
App. No.: 18/630,219
Granted: Jul 14, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Engineered lipase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. Compositions containing the engineered lipase polypeptides can be used for therapeutic and/or nutritional purposes. Polynucleotides encoding the engineered lipase polypeptides are also provided, as well as methods for making the engineered polynucleotides and lipase polypeptides.

Claims (20)

1 . A method comprising culturing a host cell to produce at least one recombinant lipase, the host cell comprising an expression vector comprising at least one recombinant polynucleotide sequence encoding the at least one recombinant lipase, the at least one recombinant lipase comprising an amino acid sequence comprising at least 70% sequence identity to SEQ ID NO: 2 and at least 80% sequence identity to SEQ ID NO: 868 and further comprising at least a substitution at position 149, 161, 174, 175, 189, 225, 271, or 293, or combinations thereof with reference to SEQ ID NO: 2.

2 . The method of claim 1 , further comprising recovering the at least one recombinant lipase.

3 . The method of claim 1 , further comprising purifying the at least one recombinant lipase.

4 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution 149A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/V/W/Y, 161A/C/D/E/F/G/H/I/K/M/N/P/Q/S/T/V/W/Y, 174A/C/D/F/G/H/I/K/L/M/N/P/Q/T/V/W/Y, 175A/C/D/E/F/G/H/I/K/L/M/N/P/R/S/T/V/W/Y, 189A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/T/V/W/Y, 225A/C/D/E/F/G/H/I/K/L/N/P/Q/R/S/T/V/W/Y, 271A/C/D/E/F/H/I/K/L/M/N/P/Q/R/S/T/V/W/Y, 293A/C/D/E/F/G/H/I/K/L/M/N/P/R/S/T/V/W/Y, or combinations thereof, wherein the positions are relative to SEQ ID NO: 2.

5 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 149, wherein the substitution is 149A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/V/W/Y.

6 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 161, wherein the substitution is 161A/C/D/E/F/G/H/I/K/M/N/P/Q/S/T/V/W/Y.

7 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 174, wherein the substitution is 174A/C/D/F/G/H/I/K/L/M/N/P/Q/T/V/W/Y.

8 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 175, wherein the substitution is 175A/C/D/E/F/G/H/I/K/L/M/N/P/R/S/T/V/W/Y.

9 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 189, wherein the substitution is 189A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/T/V/W/Y.

10 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 225, wherein the substitution is 225A/C/D/E/F/G/H/I/K/L/N/P/Q/R/S/T/V/W/Y.

11 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 271, wherein the substitution is 271A/C/D/E/F/H/I/K/L/M/N/P/Q/R/S/T/V/W/Y.

12 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution at position 293, wherein the substitution is 293A/C/D/E/F/G/H/I/K/L/M/N/P/R/S/T/V/W/Y.

13 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least a substitution 149E, 161I, 174R, 175L, 189A, 225L, 271D, or 293R, or combinations thereof.

14 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least 85% sequence identity to SEQ ID NO: 868.

15 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least 90% sequence identity to SEQ ID NO: 868.

16 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least 95% sequence identity to SEQ ID NO: 868.

17 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least 98% sequence identity to SEQ ID NO: 868.

18 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises at least 99% sequence identity to SEQ ID NO: 868.

19 . The method of claim 1 , further comprising providing the at least one recombinant lipase in a nutritional supplement or a pharmaceutical composition.

20 . The method of claim 1 , wherein the amino acid sequence of the at least one recombinant lipase comprises 100% sequence identity to SEQ ID NO: 868.